top of page

Tvardi Threrapeutics' CEO on targeting STAT3

Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3 and avoid toxicity issues.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page